Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$9.14 -4.5%	$9.14	$0.06 ▼ $14.93	$6.98M	0.94	564,810 shs	455 shs
DNAC Social Capital Suvretta Holdings Corp. III	$9.28 -7.2%	$9.56	$8.03 ▼ $10.55	$237.94M	N/A	178,857 shs	8,160 shs
IKT Inhibikase Therapeutics	$1.66 +0.3%	$1.96	$1.12 ▼ $4.20	$123.41M	0.94	244,334 shs	77,838 shs
PRME Prime Medicine	$2.57 -3.2%	$1.54	$1.11 ▼ $6.75	$338.35M	1.55	1.48 million shs	1.10 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+2.46%	+10.30%	+0.16%	-24.34%	-75.62%
DNAC Social Capital Suvretta Holdings Corp. III	0.00%	0.00%	0.00%	0.00%	0.00%
IKT Inhibikase Therapeutics	-1.20%	-2.94%	-6.78%	-27.95%	+17.02%
PRME Prime Medicine	+9.50%	+47.22%	+108.66%	+33.17%	-47.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.673 of 5 stars	3.5	0.0	0.0	0.0	1.7	1.7	0.0
DNAC Social Capital Suvretta Holdings Corp. III	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.4989 of 5 stars	3.3	1.0	0.0	0.0	0.0	0.0	1.3
PRME Prime Medicine	3.8071 of 5 stars	4.4	1.0	0.0	0.0	2.9	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	2,908.75% Upside
DNAC Social Capital Suvretta Holdings Corp. III	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	292.75% Upside
PRME Prime Medicine	2.75	Moderate Buy	$10.08	293.11% Upside

Current Analyst Ratings Breakdown

Latest DNAC, AIM, PRME, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$146K	47.83	N/A	N/A	$0.20 per share	45.70
DNAC Social Capital Suvretta Holdings Corp. III	N/A	N/A	N/A	N/A	($0.33) per share	N/A
IKT Inhibikase Therapeutics	$260K	473.22	N/A	N/A	$1.78 per share	0.93
PRME Prime Medicine	$3.85M	87.56	N/A	N/A	$1.37 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.00	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
DNAC Social Capital Suvretta Holdings Corp. III	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
DNAC Social Capital Suvretta Holdings Corp. III	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	56.37%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
DNAC Social Capital Suvretta Holdings Corp. III	N/A	0.11	0.11
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
DNAC Social Capital Suvretta Holdings Corp. III	94.13%
IKT Inhibikase Therapeutics	3.81%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
DNAC Social Capital Suvretta Holdings Corp. III	N/A
IKT Inhibikase Therapeutics	7.30%
PRME Prime Medicine	22.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
DNAC Social Capital Suvretta Holdings Corp. III	4	25.64 million	N/A	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PRME Prime Medicine	234	131.29 million	100.38 million	Optionable

DNAC, AIM, PRME, and IKT Headlines

Recent News About These Companies

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 Shares

June 24 at 4:53 AM | insidertrades.com

Insider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Purchases 21,000 Shares of Stock

June 23, 2025 | marketbeat.com

Head to Head Survey: Voyager Therapeutics (NASDAQ:VYGR) vs. Prime Medicine (NYSE:PRME)

June 20, 2025 | americanbankingnews.com

Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity

June 17, 2025 | tipranks.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in Stock

June 17, 2025 | insidertrades.com

Insider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of Stock

June 16, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in Stock

June 12, 2025 | marketbeat.com

Two Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)

June 10, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 4, 2025 | marketbeat.com

Millennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)

May 30, 2025 | marketbeat.com

Prime Medicine to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Prime Medicine's (PRME) "Neutral" Rating Reaffirmed at Citigroup

May 28, 2025 | marketbeat.com

Citigroup Downgrades Prime Medicine (PRME)

May 28, 2025 | msn.com

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty

May 27, 2025 | msn.com

6 Analysts Assess Prime Medicine: What You Need To Know

May 21, 2025 | nasdaq.com

CEO among 25% of staff out the door at cash-strapped Prime

May 20, 2025 | thepharmaletter.comT

Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff

May 20, 2025 | fiercebiotech.comF

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

May 20, 2025 | biopharmadive.comB

CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff

May 20, 2025 | bostonglobe.comB

Prime Medicine drops after cutting CGD program amid restructuring

May 20, 2025 | msn.com

Prime Medicine stock plummets amid restructuring and leadership changes

May 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Alphabet Enters a Bull Market: Is It Time to Buy?
By Ryan Hasson | June 14, 2025
View Alphabet Enters a Bull Market: Is It Time to Buy?
Target's Big Bet: Is It a Cheap Stock or a Value Trap?
By Jeffrey Neal Johnson | May 29, 2025
View Target's Big Bet: Is It a Cheap Stock or a Value Trap?
Will Warner Bros. Discovery’s Split Produce Double the Upside?
By Jeffrey Neal Johnson | June 11, 2025
View Will Warner Bros. Discovery’s Split Produce Double the Upside?
MongoDB Affirms Outlook and Accelerates Stock Price Reversal
By Thomas Hughes | June 6, 2025
View MongoDB Affirms Outlook and Accelerates Stock Price Reversal

DNAC, AIM, PRME, and IKT Company Descriptions

AIM ImmunoTech NYSE:AIM

$9.14 -0.43 (-4.49%)

As of 11:46 AM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Social Capital Suvretta Holdings Corp. III NASDAQ:DNAC

Social Capital Suvretta Holdings Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. Social Capital Suvretta Holdings Corp. III was incorporated in 2021 and is based in Henderson, Nevada.

Inhibikase Therapeutics NYSE:IKT

$1.66 +0.01 (+0.30%)

As of 11:51 AM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Prime Medicine NYSE:PRME

$2.56 -0.09 (-3.21%)

As of 11:52 AM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time